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T he Targeted Alpha Therapy Working Group defines tar-geted alpha therapy (TαT) as an agent that delivers sys-temic radiation selectively to cancer cells and the tumor
microenvironment to control cancer while minimizing toxic effects.
Targeted alpha therapy can be delineated into 2 primary categories
of payload delivery. The first approach uses the inherent molecular
properties of the radionuclide agent, whereby radionuclides natu-
rally accumulate incancerous tissue.For instance, thealphaparticle–
emitter radium223 is a calcium-mimetic isotope that is incorporated
into sites of increased bone turnover and osteoblastic activity
(Figure 1A).1-5 The second approach conjugates alpha particle–
emittingradionuclidestomonoclonalantibodies(mAbs)(Figure1B),1,2
peptides, or small molecules to target tumor-associated antigens
(Figure 1C),1,2 allowing for the possibility of targeting awide range of
tumor types.1,6 The emission of short-range alpha particles causes
complex double-stranded DNA breaks through high linear-energy
transfer(LET), triggeringcelldeathand, importantly,havingnoknown
resistancemechanism.5,7,8Deliveringshort-range,high-energyradia-
tion in a targetedmannermayallow for the treatment of localizedor
metastatic tumors9 with minimal toxic effects to surrounding non-
cancerous tissue. This review aims to define the TαT concept and
reviewtherationaleandconsiderationsfor itsdevelopmentandimple-
mentation as a viable treatment strategy in oncology.
Rationale for TαT
Radionuclides may be arbitrarily classified by their emission of al-
pha, beta, and Auger particles.10 The distinct characteristics that
determine the therapeutic effectiveness of a specific radionuclide
include theirpotential rangewhenemitted, their effective traveldis-
tance in tissue, themagnitude of energy emitted, and their relative
biologicaleffectiveness.11Particlesemittedbyradionuclidedecaycan
be categorized as low-LET or high-LET radiation, which is a mea-
sure of the energy released per unit distance.9,12,13 High-LET alpha
particlesaremorecytotoxic thanare low-LETbetaparticles.9,12Beta
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particlesareemittedelectrons (chargeof –1) thathavea lowLET(0.2
keV/μm)and relatively long (1-10mm) range in tissue.12-14Alphapar-
ticles consist of a helium nucleus with a charge of +2 and have sig-
nificantly greatermass than do beta particles.11,12,14 Alpha particles
have an LET range of 50 to 230 keV/μm7,12-14 and a travel distance
in tissue of typically 50 to 100 μm (Figure 2).12,14 The compara-
tively reduced “crossfire effect” of alphaparticle radiation results in
reduced toxic effects to surrounding healthy tissue.14
Beta particles produce sparse ionization events and individual
DNAlesions,whicharemostly repairablesingle-strandedanddouble-
strandedDNAbreaks that have a lowprobability of being lethal.7,14
Conversely, a single alpha particle can induce a greater number of
ionizationeventsandclustersofdouble-strandedDNAbreaks,which
often result in cell-cycle arrest followedbymitotic cell death, apop-
tosis, or necrosis.7,9,14 Clusters of DNA lesions are far more difficult
to repair than thebreaks inducedby theemissionofbetaparticles.15
Moreover, alpha particle–induced cell damage has been shown to
induce immunogenic cell death, and targetedalpha therapies could
potentially augment the efficacy of immuno-oncology or other an-
ticancer agentswhen used in combination. Alpha particle–induced
cell damagecangenerate antigen-specific T-cell responses, and the
immunostimulatory environment created by TαT can be exploited
to achieve a robust and effective antitumor response.16 In addi-
tion, alpha particle irradiation can induce a number of off-target ef-
fects, including thegenerationof radical oxygen species, the induc-
tion of the DNA damage response, and the repair and activation of
stress signals relating to forms of radiation injury and apoptosis. In
vivo evidence also indicates that the off-target radiation effects re-
sulting in tumor regressionareobservedat sitesdistant fromthesite
of irradiation, suggesting a systemic abscopal effect.17
Developments in the targeted delivery of radionuclides and in
radionuclideconjugationchemistry, and the increasedavailabilityof
alpha particle emitters appropriate for clinical use, have led to clini-
cal trials evaluating the safety and efficacy of TαTs across multiple
indications.7,14 The potential of alpha particle emitters to treat can-
cer has been recognized for more than a century.7 The first clinical
trial of a TαT in 1997 used the radionuclide bismuth 213 conjugated
to the leukemia antibody HuM195.7
Considerations for Isotope and Conjugation
Choices for TαT
Alpha Particle–Emitting Isotopes
More than 100 radionuclides emit alpha particles as they undergo
radioactive decay; however, the number of isotopes with the ap-
propriate properties for consideration of a TαT suitable for clinical
use in cancer treatment is limited.18,19 Alpha particle–emitting iso-
topes appropriate for cancer therapy must have a short half-life to
limit the long-termtoxiceffectsof radiationbutmust still havea long
enough half-life for practical production, preparation, and admin-
istration.
Another important consideration for TαT is the decay pattern
of alphaparticle–emitting isotopes. Thedaughter isotopes (thenu-
clide remainingafter radioactivedecay) shouldpreferablydecaysuf-
ficiently rapidly to ensure that all subsequent radiation is restricted
to the targeted tumor and to allow for rapid clearance to avoid
off-target toxic effects. Furthermore, the association between the
Figure 1. Mechanisms of Targeted Alpha Therapy (TαT)
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A, Molecular-mediated TαT is reliant on the inherent chemical properties of the
alpha particle–emitting isotope to incorporate into target tissues. The example
shown is radium 223, an alpha particle emitter and a calcium-mimetic isotope. It
can be incorporated into sites of increased bone turnover and osteoblastic
activity. B, Monoclonal antibody (mAb)–mediated TαT. Alpha particle–emitting
radionuclides are conjugated tomAbs to facilitate delivery of the radionuclide
to targeted tumor-associated antigen epitopes on tumor cells. The example
shown is the N-hydroxysuccinimide-activated 3,2-hydoxypyridinone chelator
coupled to lysine residues of the desired antibody, which is radiolabeled with
thorium 227. C, Small-molecule–mediated TαT. The example shown is actinium
225 conjugated to DOTA [(CH2CH2NCH2CO2H)4]–based prostate-specific
membrane antigen 617 (PSMA-617),1 which targets and delivers actinium 225 to
PSMA-expressing prostate cancer cells. Adapted from chapter 4 in Biomedical
Engineering–Frontiers and Challenges under CC-BY-NC-SA 3.0 license.2
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kineticsofdaughter isotopedecayand thekineticsof tumorgrowth
mustbeconsideredwhenselectingan isotope forpotential therapy.
Aggressive tumor typesmaybenefit fromtheuseof an isotopewith
a short half-life to maximize dose rate and intensity. Treatment of
indolent tumor types, in contrast, may benefit from an alpha-
emitting radionuclide with a longer half-life, allowing for sustained
alpha particle bombardment of the targeted tumor and tumor
microenvironment.
Targeted Delivery of Alpha Particle–Emitting Isotopes
Therapeutic agents that use alpha particle–emitting radionuclides
must use their inherent tissue-targeting properties or require the
stable conjugation of the radionuclide to a targeting moiety to fa-
cilitate tumor recognition. The stability of TαTs in vivo is depen-
dent on the chemical nature of the parent radionuclide. For in-
stance, the chemical properties of the halide astatine 211 facilitate
direct radiolabeling of mAbs.12,18 Other alpha-emitting radionu-
clides possess metallic properties and require chelation chemistry
to label antibodies, peptides, and small molecules.12,14,20-33 How-
ever, some radionuclides are not able to stably interactwith chelat-
ing agents. For example, radium 223 chelation and conjugation to
biomolecules have been largely unsuccessful.34 If the alpha par-
ticle emission energy or recoil energy of the daughter radionuclide
exceeds thebindingenergyof the chelating agent, thedaughter ra-
dionuclide may not be retained at the target site, leading to off-
target toxic effects.34
Monoclonal Antibody, Peptide, and Small-Molecule
Conjugates
The primary advantage of using tumor-specific mAbs in TαT is the
specificity and affinity for tumor-associated antigen epitopes on tu-
mor cells. Full-length mAbs contain 2 identical fragment antigen–
bindingregionsandafragmentcrystallizableorconstantregion.35Sev-
eralpotentialdisadvantageshavebeenidentifiedwiththetherapeutic
useof full-lengthmAbs,whichmayaffect theuseof full-lengthmAb–
mediated TαT. The high molecular weight of mAbs results in a long
serumhalf-life,andthenonspecificuptakeoftheantibodyviathefrag-
mentcrystallizable region incells of the innateandadaptive immune
system may lead to nontargeted irradiation.14,35 Nonspecific mAb-
mediated TαT interaction with myeloid and hepatic sinusoidal cells
can result inmyelosuppressionand liver toxiceffects.14Antibodyen-
gineeringeffortshavebeenmadetodevelopantibodyfragmentsand
mAb derivatives that are smaller in size and lack a fragment crystal-
lizable region to shorten serum half-life and limit off-target uptake
withoutsacrificingspecificityandaffinity.35SmallerengineeredmAb
derivativesclear thecirculationmorerapidlyandpenetrate target tu-
morsmoreeffectively,providing increasinglyfavorabletumortoback-
ground ratios.14,35
In addition to full-length mAb and engineered mAb fragment
use, ligands, synthetic protein scaffolds, and substrate analogues
can also be used as TαT targeting agents. Examples include the
conjugation of thorium 227 to a full-length mesothelin antibody
to target mesothelin-expressing cancer cells and the conjugation
of actinium 225 to the small-molecule, prostate-specific mem-
brane antigen 617 to target prostate cancer cells.1,36 The use of
these targeting moieties results in shorter serum half-lives and
rapid targeted uptake into tumors.14,35 However, the use of affi-
bodies and nanobodies can result in increased risk of off-target
toxic effects, notably renal toxic effects due to increased renal
retention.14
Radium 223: TαT Clinical Proof of Concept
The first approved TαT to treat cancer was radium 223.4,37,38 As a
calcium mimetic, cationic radium 223 is actively incorporated into
hydroxyapatite [Ca5(PO4)3OH],
14 an integral component of the
inorganic bone matrix, and delivers ionizing radiation to areas of
increased osteoblastic activity (Table 1).4,14,39-48 Radium 223 is
typically produced in a generator from actinium 227 (half-life, 21.7
years). Radium 223 has a half-life of 11.4 days and emits 4 alpha
particlesvia itsdecaychainscheme(eFigure,A intheSupplement).48
Ninety-fourpercentof the total decayenergyof radium223 is emit-
ted as alpha particles.
Because the actinium227precursor has ahalf-life of 21.7 years,
large amounts of radium 223 can be efficiently produced over the
Figure 2. Relative Alpha Particle vs Beta Particle Emission Range in Tissue
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longterm.48The11.4-dayhalf-lifeof radium223allowssufficient time
for preparation, distribution, and patient administration.49
Dual Mode of Action of Radium 223
Radium223 represents themost studiedTαT inpreclinical andclini-
cal settings and exemplifies themechanismof action of TαT. In ani-
mal models, radium 223 exhibits a dual mode of action that inter-
feres with the progression of bonemetastatic disease in advanced
prostate cancer.5 Prostate cancer cells alter bone structure and sta-
bility bymodifyingosteoblast function to stimulate abnormal bone
formation, resulting in fragile, disorganized bone that contributes
to skeletal-related events and affects overall survival.5,50,51 The ac-
cumulation of radium 223 in the tumor microenvironment sup-
presses tumor-induced abnormal bone formation and induces tu-
morcell death.5The rapiddecaycascadeof radium223and its alpha
particle–emitting daughter isotopes is cytotoxic to bothmalignant
cells and bone cells in osseous metastases.3 Studies in mice have
shownthat less than 1%of radium223decayproductsmigrateaway
fromthebone, thereby limiting the toxiceffects andmaximizing the
exposure of bonemetastases to alpha particle radiation.3
Exposure to radium 223 has been shown to induce immuno-
genicmodulation in tumor cells and antigen-specific T-cell responses
invitro.16Exposureofhumanprostate,breast,and lungcarcinomacell
lines to radium 223 resulted in the upregulation of HLA-ABC antigen
and calreticulin and a significant increase in T-cell–mediated killing of
carcinomacells.16Theabilityof radium223topromote immunogenic
modulationintumorcellsandenhanceT-cell–mediatedcell lysisacross
humantumorcell linessuggestsbroadapplicabilityandapotential for
combinationwith immuno-oncology agents.
Approval of Radium 223 for the Treatment
of Prostate CancerWith BoneMetastases
Radium223 is the firstTαTapproved for the treatmentof castration-
resistant prostate cancer (CRPC) with bone metastases.38,52 Pa-
tients receive 6 slow intravenous injections lasting up to 1 minute
at a dose of 55 kBq/kg every 4weeks.4,37 Basedon the results from
the phase 3 ALSYMPCA (Alpharadin in Symptomatic Prostate Can-
cer) trial that enrolled 921 patients, radium 223 treatment in com-
bination with the best standard of care resulted in significant im-
provement in overall survival compared with placebo plus best
standard of care,withmedian overall survival of 14.9months in the
radium223 arm (11.3months in the placebo arm) conferring a 30%
reduction in the risk of death (hazard ratio, 0.70; 95% CI, 0.58-
0.83; P < .001) (Table 1).4,39-47 Overall, radium 223 treatment was
well toleratedanddemonstratedagood safetyprofile attributed to
its short alpha particle range and localized delivery. Aside from in-
frequent all-grade thrombocytopenia (12% of patients who re-
ceived radium 223 and 6% of patients who received placebo) and
all-gradeneutropenia (5%ofpatientswho received radium223and
1%ofpatientswho receivedplacebo), hematologic safetywas simi-
lar between radium 223 and placebo. Long-term follow-up of pa-
tients in the ALSYMPCA trial demonstrated that radium 223 treat-
mentcontinuedtobewell tolerated,withminimalmyelosuppression
and conservation of hematopoietic function.53 Secondary primary
malignantneoplasms,definedashistologicallydifferent fromthepri-
mary cancer, occurred in 5 patients treated with radium 223 (1 had
carcinomaofunknownorigin, 1 had squamous cell carcinoma, 1 had
intestinal adenocarcinoma, and 2 had skin neoplasms) and in 2 pla-
cebo-treatedpatients (1hadaneoplasmofunknownoriginand1had
gastric cancer). In particular, patients treated with radium 223 did
notdevelopnewprimarybonecancerduring the3-year follow-up.53
A longer follow-up period (7 years) is being investigated in an
observational study.54
Ongoing and Recent Studies of Radium 223
Thepotential of radium223 in combinationwithother agents is un-
der investigation across a range of advanced cancers. Currently, ra-
dium223 isbeing tested in2 largephase3 trials in combinationwith
novel antihormonal agents in the chemotherapy-naive setting of
asymptomatic or mildly symptomatic prostate cancer with bone
metastases.55,56 Recently, a phase 3 randomized clinical trial of ra-
dium 223 vs placebo, each in combination with abiraterone ac-
etateplusprednisone for chemotherapy-naivepatientswithasymp-
tomatic or mildly symptomatic CRPC with bone metastases (ERA
223; NCT02043678), was prematurely unblinded.57 The indepen-
dentdatamonitoringcommittee recommendedunblinding the trial
owing to the observation ofmore fractures and deaths in the com-
bination treatment arm. Unblinded data from the study are cur-
rently being analyzed to confirm the preliminary findings of the in-
dependentdatamonitoringcommittee.Giventhese results fromthe
ERA 223 trial, the current recommendation is not to combine ra-
dium 223 with abiraterone acetate and prednisone.57 The phase 3
Table 1. Rates of Overall Survival of Approved Radionuclide Therapies
Approved Radionuclide Therapy Data on Overall Survival
Alpha particle emitter
Radium 223 for prostate cancer
Parker et al,4 2013 (phase 3) 14.9 mo (radium 223) vs 11.3 mo
(placebo) (HR, 0.70; 95% CI, 0.58-0.83;
P < .001)
Beta particle emitter
Strontium 89 for prostate
cancer
Porter et al,39 1993 (phase
3)
6.3 mo (strontium 89) vs 7.9 mo
(placebo) (P = .60)
Sciuto et al,40 2002 (phase
3)
9.0 mo (strontium 89) vs 6.0 mo
(placebo) (P = .30)
Quilty et al,41 1994 (phase
3)
8.3 mo (strontium 89) vs 7.0 mo (XRT)
(P = .10)
Oosterhof et al,42
2003 (phase 3)
7.2 mo (strontium 89) vs 11.0 mo (XRT)
(P = .046)
Yttrium 90 (anti-CD20) for
NHL,43 2013
Effect on overall survival not known
Iodine 131 (anti-CD20) for
NHL,44 2012
Effect on overall survival not known
Samarium 153 for prostate
cancer
Collins et al,45 1993 (phase
1/2)
9.0 mo (92.5 MBq/kg) vs 6.0 mo (37
MBq/kg)
Resche et al,46 1997 (phase
3)
No difference between 18.5 and 37
MBq/kg of samarium 153
Lutetium 177 for GEP-NETs
Strosberg et al,47
2017 (phase 3)
PFS: NR (lutetium 177; 95% CI, NE-NE) vs
8.5 mo (placebo; 95% CI, 5.8-9.1) (HR,
0.21; 95% CI, 0.13-0.32; P < .001);
overall survival: NR (lutetium 177; 95%
CI, 31.0-NE) vs 27.4 mo (placebo; 95% CI,
22.2-NE) (HR, 0.52; 95% CI, 0.32-0.84;
P = .004)
Abbreviations: GEP-NETs, gastroenteropancreatic neuroendocrine tumors; HR,
hazard ratio; NE, not evaluable; NHL, non-Hodgkin lymphoma; NR, not reached;
PFS, progression-free survival; XRT, external radiotherapy.
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PEACE III (ProstateCancerConsortium inEurope) trial evaluating ra-
dium223 in combinationwithenzalutamide forpatientswithmildly
symptomatic or asymptomatic metastatic CRPC (mCRPC) is
ongoing.56Theresultsof thephase2,prospectiveeRADicAte (APro-
spective Evaluation Combining Radium-223 Dichloride and Abi-
raterone Acetate Plus Prednisone in Patients With Castration-
ResistantProstateCancer) studyof radium223 in combinationwith
abiraterone acetate plus prednisone for patientswithmCRPChave
recently been published.58 Of the 36 patients participating in the
open-label study, 96% reported adverse events that were grade 1
or 2, with themost frequently reported adverse events being diar-
rhea (17%), nausea (17%), and fatigue (14%). Safety follow-up oc-
curredat theendof treatment,whichwas30daysafter the final ad-
ministration of radium 223. Furthermore, neither the REASSURE
noninterventionalstudy(Ra-223Alpha-EmitterAgent inSafetyStudy
inmCRPC Population for Long-term Evaluation) nor the US and in-
ternational expanded access programs indicated that the com-
bined use of abiraterone acetate and radium 223 resulted in in-
creasednumbersof reportedadverseevents.59-62Theoptimal timing
of TαT administrationwith other cancer therapies that affect bone
pathophysiologiccharacteristics remains tobe fullyunderstood,and
some combinationsmay be better suited for layering of treatment
as opposed to simultaneous initiation.
An open-label phase 2a study showed that radium 223 treat-
ment demonstrated clinical activity as a single agent with a well-
tolerated safety profile for patientswith bone-predominant breast
cancer.63 Studiesofother cancer types, suchas renal cell cancer and
multiple myeloma, are ongoing (Table 2).64,65
Current TαT Landscape
With the overall survival benefit conferred by radium 223 treatment
and its subsequent approval for bone-predominantmCRPC, interest
in thetherapeuticpotentialofalphaparticle–emittingradionuclides is
increasing.Otheralphaparticleemittersbeing investigated inpreclini-
calandclinical studies includethorium227,actinium225,bismuth213,
astatine 211, and lead 212 (Table 2).
Thorium 227
Thorium 227 is an alpha particle emitter with a physical half-life of
18.7 days.26 The thorium 227 decay scheme is initiated by its alpha
decay into radium223,which subsequently follows thedecay chain
of radium 223 (eFigure, A in the Supplement). As thorium 227 de-
cays to stable lead 207, 5 alpha particles are released, making tho-
rium227anattractivecandidateforTαT.26Targetedthorium227con-
jugates are being investigated in several preclinical and phase 1
studiesacross tumortypes, includingprostatecancer, colorectal can-
cer, gastric cancer, ovarian cancer, non-Hodgkin lymphoma, and
leukemia.20-26 Thorium227 canbe readily conjugated tomAbs tar-
geting different cell-surface antigens across tumor types and has
demonstrated in vitro and in vivo antitumor activity.20,22-26 Tho-
rium 227 conjugated to an anti-CD22mAb is currently being inves-
tigated in anopen-label phase 1 trial forpatientswith relapsedor re-
fractoryCD22-positivenon-Hodgkin lymphomatodeterminesafety
and themaximum tolerated activity.21
Actinium 225
Thedecayof actinium225 results in theemissionof4alphaparticles,
whichmarksactinium225asanattractiveandpotentchoiceforTαT.12
Actinium 225 has a physical half-life of 9.92 days and yields 3 daugh-
ter radionuclides thateachemitanalphaparticleontheirdecay(eFig-
ure,B intheSupplement).Aswithradium223, therelatively longhalf-
lifeofactinium225allowsforcentralizedproduction,distribution,and
administrationofactinium225TαT.12,66Anotherdistinctadvantageof
actinium225–based TαT is the emission of a 440-keV γ-ray after the
decayofthebismuth213daughterradionuclide,whichcanbeusedfor
imaging to determine biodistribution.14 An ongoing phase 1/2 trial of
actinium 225–lintuzumab targeting CD33-positivemyeloid leukemia
cells in patients with acute myeloid leukemia has shown that treat-
ment is safe.27,67 The first-in-human study of actinium225–prostate-
specificmembrane antigen617 in 14heavily pretreatedpatientswith
end-stagemCRPCshowedthatatreatmentactivityof100kBq/kgwas
tolerable and had promising antitumor effects in 9 of 11 evaluable
individuals.28Noteworthyantitumoractivitywasobserved in82%of
patients as assessed by radiologic response, and 75% of patients
showed a decrease in the level of prostate-specific antigen, warrant-
ing further investigation in clinical trialswith larger patient cohorts.
Bismuth 213
Bismuth 213 has a short physical half-life of 45.6 minutes and is pre-
pared for therapeutic use in an actinium 225 and bismuth 213
generator.68Thegeneratorproducesbismuth213that isclinicallyuse-
ful for 10 days.30 Bismuth 213 decays to stable bismuth 209 through
theemissionofanalphaparticleand2betaparticles (eFigure,B in the
Supplement).Bismuth213isreadilyconjugatedtomAbs,peptides,and
smallmolecules and has been investigated as a TαT in several clinical
trials.12,29,69However, its shorthalf-lifeandconjugationchemistry re-
stricttheuseofbismuth213forpatients.66Despitethesepractical limi-
tations,clinical trialshaveshownpromisingefficacyofbismuth213. In
a phase 1 study, Jurcic et al69 usedbismuth213 conjugated to thehu-
manizedanti-CD33antibodyHuM195(lintuzumab),whichtargetsmy-
eloid leukemiacells, totreat18patients. Injectionofbismuth213–CHX-
Table 2. Targeted Alpha Therapies Being Investigated
in Ongoing Clinical Trials
Isotope and Targeting Mechanism Tumor Type or Indication Phase
Radium 223
Molecular mediated Prostate cancer 1-3
Molecular mediated Breast cancer 2
Molecular mediated Multiple myeloma 1/2
Molecular mediated Renal cell carcinoma 1/2
Thorium 227
Monoclonal antibody NHL 1
Actinium 225
Monoclonal antibody Multiple myeloma 1
Monoclonal antibody Prostate cancer 1
Monoclonal antibody AML 1/2
Astatine 211
Monoclonal antibody AML, ALL, and MDS 1/2
Lead 212
Monoclonal antibody ERBB2/HER2-positive tumors 1
Abbreviations: AML, acute myeloid leukemia; ALL, acute lymphoblastic
leukemia; MDS, myelodysplastic syndrome; NHL, non-Hodgkin lymphoma.
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A-DTPA-HuM195 did not result in toxic effects associated with the
infusions.69 In a phase 1/2 study investigating the treatment of 31 pa-
tients with newly diagnosed or relapsed or refractory acute myeloid
leukemiawithcytarabinefollowedbybismuth213–HuM195,thetreat-
mentwas shown to be tolerable andwas able to produce remissions
inpatients.68However,myelosuppressionwasthemostcommontoxic
effectassociatedwithtreatment.Thisclinicalproofofconcept for the
use of bismuth 213 as a viable TαT has encouraged further investiga-
tion for patients with non-Hodgkin lymphoma, melanoma, and
glioblastoma.14
Astatine 211
Astatine 211 has a physical half-life of 7.2 hours and decays through
a branchedpathway,with each decay path producing an alpha par-
ticle as it decays to stable lead207 (eFigure, C in theSupplement).18
Astatine 211 has several attractive features for use as a TαT, includ-
ing no long-lived alpha particle–emitting daughter radionuclides,18
photon emission that allows imaging, and compatibility for conju-
gationwith several carriermolecules toallow targeteddelivery.18,66
The availability of astatine 211 is limited by its short half-life, which
makes it difficult todeliver sufficientquantitiesof astatine211 todis-
tant treatmentcentersandhas limited thenumberofpreclinical and
clinical studies of this radionuclide.18,66
Astatine 211 can be used to radiolabel mAbs33 and small mol-
ecules, including thymidine analogues,32 biotin analogues, and
bisphosphonate complexes.14,18 To date, astatine 211 has been in-
vestigated in 2 phase 1 clinical trials.33,70 Treatment with chimeric
antitenascinmAb81C6 (ch81C6) labeledwith astatine 211 (astatine
211–ch81C6) for 18 patients with recurrent malignant brain tumors
resulted in minimal toxic effects, with no dose-limiting toxic ef-
fects after administrationof single activitiesof up to347MBq.33As-
tatine 211–ch81C6 treatment also resulted in promising survival in
this phase 1 trial. The second phase 1 trial demonstrated that asta-
tine 211–labeled MX35 F(ab′)2 could be safely administered, with-
out observed toxic effects, for 9 patients with advanced ovarian
cancer.70 However, several studies of astatine 211–labeled com-
poundsof interest havebeenhaltedowing to the lackof in vivo sta-
bility of these compounds.18 Premature release of unbound asta-
tine 211 in vivo has been observed,which can result in irradiation of
nontarget tissues, including physiological accumulation in the thy-
roidandstomach.18Toavoid toxiceffects, highly stableastatine211–
labeled compoundsmust be developed for further study.
Lead 212
Lead212 isabetaparticleemitterwithaphysicalhalf-lifeof 10.2hours;
it is the immediateparental radionuclideofbismuth212.12Bismuth212
decays tostable lead208throughtheemissionof 1alphaparticleand
1 beta particle12 (eFigure, D in the Supplement). The first phase 1 trial
investigatingtheadministrationof lead212conjugatedtotrastuzumab
for patients with ERBB2/HER2-positive ovarian cancer showedmini-
mal toxiceffects.31 Inaddition, therewas limitedredistributionof lead
212–TCMC[S-2-(4-isothiocyanatobenzyl)-1,4,7,10-tetraaza-1,4,7,10-tetra
(2-carbamoylmethyl)cyclododecane)]–trastuzumaboutsidetheperi-
toneal cavity, further demonstrating its safety.31
Challenges and Optimization for Future
Clinical Study
TheconceptofTαT for cancer treatmenthasbeendiscussed forde-
cades. Targeted alpha therapy combines the affinity and specificity
of molecular targeting with potent, cytotoxic alpha particle emis-
sions to deliver systemic, high-energy radiation selectively to can-
cer cells and the tumor microenvironment to control cancer. Be-
cause there are no known resistancemechanisms to alpha particle
radiation that have been documented, TαT represents a different
treatment approach and provides an avenue of treatment to by-
pass mechanisms of acquired resistance in selected tumors. Fur-
thermore, the evident rationale for combining TαTs with other on-
cologyagents(eg, immunecheckpoint inhibitors,DNAdamagerepair
pathway inhibitors,orT-cell–based immunotherapy)allowsforamul-
tifaceted approach to cancer treatment.
Malignant cells may, however, develop resistance to a particu-
larmechanismofdelivery. For instance, prostate cancer tumor cells
could evolve todownregulate surfaceprostate-specificmembrane
antigenexpressionon the cell in response to antibody-mediatedor
small-molecule–mediatedTαT, therebyrenderingcontinuedtherapy
less effective. The development of novel radionuclide conjugation
strategieswill be required to overcome targeting limitations due to
acquired resistance and address the problem of tumor types that
have a low physiological uptake of radionuclides.
Conclusions
Asanemerging treatment approach, TαTprovides thepossibility to
bypassmechanisms of acquired resistance in selected tumors. The
clinical success (establishedefficacy and favorable safetyprofile) of
the first TαT, radium 223, in treatingmCRPCwith bonemetastases
has demonstrated the proof of concept for TαT. Future studies in-
vestigatingmore TαT optionsmay lead to additional treatment ap-
proaches for many cancer types.
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